Ultime notizie per Illumina (NASDAQ:ILMN) Azioni

ILLUMINA INC

Illumina

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

jim cramer chart shutter

News

Markets

Media

Trading Ideas

ACHR

ANET

ILMN

LRCX

PLTR

TSLX

L&#39;esperto di mercato svela le sue strategie: quali titoli premiare e quali abbandonare per navigare con successo il mercato azionario?

Cramer scatenato: cosa comprare, vendere e cosa evitare assolutamente

ABSI

ACCD

ARKG

ARKK

ARKQ

ARKX

ESLT

NTLA

OKLO

PATH

Scopri come queste strategie potrebbero influenzare il mercato e cosa riserva il futuro per questi investimenti.

Ecco in quali società sta investendo Cathie Wood tramite Ark

Analyst Color

Long Ideas

Health Care

Analyst Ratings

Tech

General

NVDA

Scopriamo come l&#39;intelligenza artificiale stia rivoluzionando il settore sanitario, con analisi delle opportunità e delle potenziali sfide.

Intelligenza artificiale nella sanità: è la prossima scommessa di Nvidia

Illumina Inc

Illumina Inc COM-WHEN ISSUED

<a href="https://www.statnews.com/2025/06/25/nih-halts-research-grant-terminations-email-shows/?utm_campaign=twitter_organic&amp;utm_medium=social&amp;utm_source=twitter">https://www.statnews.com/2025/06/25/nih-halts-research-grant-terminations-email-shows/?utm_campaign=twitter_organic&amp;utm_medium=social&amp;utm_source=twitter</a>

BRKR

QTRX

'NIH halts grant terminations 'effective immediately,' email says'- Stat News

Barclays analyst Luke Sergott maintains Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) with a Underweight and raises the price target from $77 to $85.

Price Target

Barclays Maintains Underweight on Illumina, Raises Price Target to $85

On Monday, Illumina, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) agreed to acquire Standard BioTools&#8217; (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAB#NASDAQ">LAB</a>) subsidiary, SomaLogic.
Following the announcement of the acquisition, Standard BioTools&#8217; stock experienced a significant surge.
The deal consideration includes $350 million in cash payable at closing plus up to $75 million in near-term performance-based milestones and&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/n46048517/illumina-to-acquire-somalogic-accelerating-its-proteomics-business-and-advancing-the-companys-mult" rel="noreferrer noopener">performance-based royalties</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/46056104/why-is-compass-pathways-stock-trading-lower-on-monday" rel="noreferrer noopener">Why Is Compass Pathways Stock Trading Lower On Monday?</a>
&#8220;The acquisition of SomaLogic will enhance Illumina&#8217;s presence in the expanding proteomics market and advance the multiomics strategy we announced in 2024. This will strengthen the value of the NovaSeq X product today and unlock greater capabilities in the future,&#8221; said Jacob Thaysen, <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">CEO of Illumina</a>.
&#8220;Illumina and SomaLogic have partnered closely for more than three years, and this combination&nbsp;increases our ability to serve our customers and accelerate our technology roadmap towards advanced biomarker discovery and disease profiling,&#8221; Thaysen added.
The transaction builds on a co-development agreement Illumina established with SomaLogic in December 2021 to bring the SomaScan Proteomics Assay onto Illumina&#8217;s high-throughput next-generation sequencing (NGS) platforms.
Illumina Protein Prep is currently in use with nearly 40 early-access customers globally and will become available to all customers starting in the third quarter of 2025.
Combining SomaLogic&#8217;s proteomics technology with Illumina&#8217;s NGS ecosystem,&nbsp;DRAGEN software, and Illumina Connected Multiomics will accelerate the technology development roadmap for proteomics and reduce the time and cost of proteomic research.
SomaLogic has approximately 250 employees worldwide.
This transaction brings SomaLogic&#8217;s aptamer-based affinity proteomics platform into Illumina&#8217;s portfolio, enhancing Illumina&#8217;s presence in a high-growth area within the proteomics market.
The kitted NGS-based panels business will add a high-margin consumables revenue stream.
Illumina expects the business to become profitable in 2027 on a non-GAAP operating income basis and for non-GAAP operating margins to be in line with Illumina in 2028.
Illumina expects to close the transaction in the first half of 2026.
Price Action: LAB stock is up 33.8% at $1.41, and ILMN stock is up 0.09% at $90.57 at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/biotech/25/05/45471704/icahn-ramps-up-bets-on-genes-and-jets-illumina-stake-jumps-450-jetblue-holding-grow-90" target="_blank" rel="noreferrer noopener">Icahn Ramps Up Bets On Genes And Jets: Illumina Stake Jumps 450%, JetBlue Holding Grow 90%</a></li>
</ul>
Photo via Shutterstock

Movers

SomaLogic Acquisition Marks Next Step In Illumina's Advanced Biomarker Push

WIIM

ILMN stock has given up its prior gain. Standard BioTools shares were trading higher after the company announced a strategic sale of SomaLogic to Illumina.

CORRECTION: Standard BioToles Ticker Is "LAB" Not "ILMN"

Up To $425 Million In Total Proceeds Inclusive of Near-term Milestone Payments; $350 Million In Upfront Cash&nbsp;&nbsp;
Retains Strategic Upside with Illumina Protein Prep Royalty Stream and Rights to Single SOMAmer Reagent Business &nbsp; Simplifies Operating Structure and Enables Achievement of Adjusted EBITDA Break-Even &nbsp; Cash &amp; Cash Equivalents of At Least $550 Million Expected at Close to Fuel Inorganic Growth Strategy and Drive Long-Term Value Creation
SOUTH SAN FRANCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAB#NASDAQ">LAB</a>) (the "Company" or "Standard BioTools") today announced the strategic sale of SomaLogic to Illumina, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) ("Illumina"), including SomaScan&#xAE; Assay Services, Authorized Sites and KREX&#x2122; for an upfront payment of $350 million in cash at closing and up to $75 million in cash in near-term milestone payments, for aggregate cash consideration of up to $425 million, plus specified sales royalties on SOMAmer-based next-generation sequencing (NGS) library preparation kits (Illumina Protein Prep). Standard BioTools will retain certain Single SOMAmer reagent commercialization rights. The transaction significantly simplifies the operating structure of Standard BioTools and enables the achievement of adjusted EBITDA break-even.
The transaction is expected to close in the first half of 2026, subject to receipt of required regulatory approvals, including receipt of clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, and satisfaction of other customary closing conditions. The transaction has been unanimously approved by both the Standard BioTools Board of Directors and a Special Committee of the Standard BioTools Board of Directors.

Standard BioTools Sells SomaLogic To Illumina For Up To $425M, Plus Future Royalties

Illumina shares are trading higher after the company announced it was selected by Incyte and QIAGEN to advance precision diagnostics for CALR-driven myeloproliferative neoplasms.

<ul>
<li>QIAGEN to create a multimodal panel using next-generation sequencing (NGS) technology for detecting clinically relevant gene alterations in hematological malignancies</li>
<li>Companion diagnostic to identify key disease-causing mutations in patients with MPNs, with an initial focus on mutant CALR the second most common driver of MPNs</li>
<li>Panel to be validated on Illumina NextSeq 550Dx platform for use with whole blood samples</li>
<li>Partnership supports Incyte's extensive portfolio in myeloproliferative neoplasms, including INCA033989, and enhances QIAGEN's onco-hematology diagnostics pipeline</li>
</ul>

INCY

QGEN

Reported Sunday, Incyte Taps QIAGEN And Illumina Technology To Advance Precision Diagnostics For CALR-Driven Myeloproliferative Neoplasms

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Needham raised Lumentum Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITE#NASDAQ">LITE</a>) price target from $100 to $105. Needham analyst Ryan Koontz maintained a Buy rating. Lumentum shares closed at $81.96 on Tuesday. See how other analysts <a href="https://www.benzinga.com/quote/lite/analyst-ratings">view this stock</a>.</li>
<li>Telsey Advisory Group cut the price target for Academy Sports and Outdoors, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASO#NASDAQ">ASO</a>) from $60 to $58. Telsey Advisory Group analyst Cristina Fernandez maintained an Outperform rating. Academy Sports and Outdoors shares closed at $44.60 on Tuesday. See how other analysts view <a href="https://www.benzinga.com/quote/aso/analyst-ratings">this stock</a>.</li>
<li>HC Wainwright &amp; Co. raised Insmed Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) price target from $90 to $120. HC Wainwright &amp; Co. analyst Andrew Fein maintained a Buy rating. Insmed shares closed at $90.93 on Tuesday. <a href="https://www.benzinga.com/quote/insm/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Canaccord Genuity raised the price target for Illumina, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) from $87 to $99. Canaccord Genuity analyst Kyle Mikson maintained a Hold rating. Illumina shares closed at $87.98 on Tuesday. <a href="https://www.benzinga.com/quote/ilmn/analyst-ratings">See how other analysts view this stock.</a></li>
<li>BTIG slashed the price target for GitLab Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTLB#NASDAQ">GTLB</a>) from $86 to $67. BTIG analyst Gary Powell maintained a Buy rating. GitLab shares closed at $48.51 on Tuesday. See how other analysts <a href="https://www.benzinga.com/quote/gtlb/analyst-ratings">view this stock</a>.</li>
<li>Benchmark raised TAT Technologies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TATT#NASDAQ">TATT</a>) price target from $35 to $36. Benchmark analyst Josh Sullivan maintained a Buy rating. TAT Technologies shares settled at $26.40 on Tuesday. <a href="https://www.benzinga.com/quote/tatt/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo raised Marathon Petroleum Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPC#NYSE">MPC</a>) price target from $180 to $182. Wells Fargo analyst Roger Read maintained an Overweight rating. Marathon Petroleum shares closed at $162.64 on Tuesday. <a href="https://www.benzinga.com/quote/mpc/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Wells Fargo cut Phillips 66 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSX#NYSE">PSX</a>) price target from $149 to $147. Wells Fargo analyst Roger Read maintained an Overweight rating. Phillips 66 shares closed at $118.70 on Tuesday.  <a href="https://www.benzinga.com/quote/psx/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>BTIG increased the price target for Super Group (SGHC) Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SGHC#NYSE">SGHC</a>) from $9 to $11. BTIG analyst Clark Lampen maintained a Buy rating. Super Group shares settled at $9.30 on Tuesday. <a href="https://www.benzinga.com/quote/sghc/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS raised Datadog, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDOG#NASDAQ">DDOG</a>) price target from $125 to $140. UBS analyst Karl Keirstead maintained a Buy rating. Datadog shares closed at $119.91 on Tuesday. <a href="https://www.benzinga.com/quote/ddog/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying DDOG stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/DDOG/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="583" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/11091354/image-163-1024x583.png" alt="" class="wp-image-946172" style="width:622px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/11091354/image-163-1024x583.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/11091354/image-163-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/11091354/image-163-768x437.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/11091354/image-163.png 1112w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45858699/top-2-tech-and-telecom-stocks-you-may-want-to-dump-in-q2">Top 2 Tech And Telecom Stocks You May Want To Dump In Q2</a> </li>
</ul>
Photo via Shutterstock

DDOG

GTLB

INSM

LITE

SGHC

TATT

Datadog To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Wednesday

Analysts' ratings for Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) over the last quarter vary from bullish to bearish, as provided by 11 analysts.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Illumina and provided 12-month price targets. The average target is $103.73, accompanied by a high estimate of $185.00 and a low estimate of $77.00. A decline of 11.21% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1749643271_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Illumina among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kyle Mikson</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Hold</td>
<td>$99.00</td>
<td>$87.00</td>
</tr>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$105.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$185.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Tejas Savant</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$100.00</td>
<td>$136.00</td>
</tr>
<tr>
<td>Kyle Mikson</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$87.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Julia Qin</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$85.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Subbu Nambi</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$114.00</td>
<td>$122.00</td>
</tr>
<tr>
<td>Kyle Mikson</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$92.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$77.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Conor McNamara</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$112.00</td>
<td>$128.00</td>
</tr>
<tr>
<td>Patrick Donnelly</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$85.00</td>
<td>$90.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Illumina. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Illumina compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
For valuable insights into Illumina's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ILMN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Illumina analyst ratings.</a>
<h2>Discovering Illumina: A Closer Look</h2>
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
<h3>Financial Insights: Illumina</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Negative Revenue Trend: Examining Illumina's financials over 3M reveals challenges. As of 31 March, 2025, the company experienced a decline of approximately -3.25% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Illumina's net margin excels beyond industry benchmarks, reaching 12.58%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Illumina's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 5.53%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Illumina's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.1% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 1.1, caution is advised due to increased financial risk.
<h2>The Significance of Analyst Ratings Explained</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down Illumina: 11 Analysts Share Their Views

Canaccord Genuity analyst Kyle Mikson maintains Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) with a Hold and raises the price target from $87 to $99.

Canaccord Genuity Maintains Hold on Illumina, Raises Price Target to $99

New AI algorithm accurately deciphers pathogenic regulatory genetic variants in the noncoding regions of the human genome at scale for the first time
SAN DIEGO, May 29, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) today unveiled PromoterAI, a new AI algorithm that accurately deciphers pathogenic regulatory genetic variants in the noncoding regions of the human genome. A study <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4438250-1&amp;h=2291622851&amp;u=https%3A%2F%2Fwww.science.org%2Fdoi%2F10.1126%2Fscience.ads7373&amp;a=published+today">published today</a> in Science illustrates how this deep learning technology discovered regulatory variants in noncoding "promoter" segments that contribute up to 6% of the genetic causes of rare diseases. By turning data into insights, this technology is expected to help researchers accelerate new breakthroughs in diagnosis for rare diseases.
Currently, only about 30% of rare disease patients receive an accurate diagnosis from exome sequencing. For many patients, insights may be hidden in what are known as "noncoding regions," which comprise over 98% of the genome and may hold the key to increasing the diagnostic rate.
PromoterAI will be accessible through Illumina Connected Software and it is available today as part of DRAGEN&#x2122; secondary analysis. Precomputed PromoterAI scores for all human promoter single-nucleotide variants are freely available for academic and noncommercial research use. Illumina Connected Software supports seamless integration with next-generation sequencing and array workflows for genomics and multiomics. Researchers, bioinformaticians, and clinical geneticists can use Illumina Connected Software to prioritize variants that are important to a case, gain critical insights, and accelerate their precision medicine dry lab operations.

Illumina Unveils PromoterAI, New AI Algorithm That Accurately Deciphers Pathogenic Regulatory Genetic Variants In Noncoding Regions Of Human Genome

Following FDA approval last year, Illumina's TSO Comprehensive test gains broad payer reimbursement, expanding access to comprehensive genomic profiling to match patients with targeted therapies
Illumina's IVD portfolio will also expand to offer Pillar oncoReveal&#xAE;&nbsp;CDx, the newest panel to deliver critical companion diagnostic testing using the Illumina MiSeq&#x2122; Dx System
SAN DIEGO, May 28, 2025 /PRNewswire/ --&nbsp;Illumina Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) today announced an expanded clinical oncology portfolio, unlocking the next new solutions to advance precision oncology and improve the standard of care. The company's broad range of clinical offerings will accelerate access to precision oncology for more patients with cancer. Illumina tumor profiling and in vitro diagnostic (IVD) solutions will be on display at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
TSO Comprehensive is now covered under Medicare plans by the Centers for Medicare &amp; Medicaid Services (CMS), as well as most commercial health plans.
Illumina continues to pursue expanded biomarker indications and CDx claims for TSO Comprehensive in the US. Also announced today, the IVD kit has now received regulatory approval in Japan.

Illumina Expands Clinical Oncology Portfolio, Unlocking Next New Solutions To Advance Precision Oncology And Improve Standard Of Care

Cathie Wood, the founder, CEO, and CIO of Ark Invest, underscored the application of artificial intelligence in the healthcare sector by sharing new research by Mass General Brigham, citing the discovery of cancer survival using facial photograph analysis.
What Happened: Wood reiterated her earlier point on the &#8220;profound application&#8221; of AI in the healthcare industry, comparing it to the implementation of the same in autonomous vehicles and humanoid robots.
She quoted Dr. Peter H. Diamandis, the founder of Abundance360 and XPRIZE, who highlighted Mass General Brigham research.
According to the researchers at Mass General Brigham, AI was not only able to estimate a person&#8217;s biological age, but also improve cancer survival outcomes predictions by just analyzing a facial photograph.
Thus, this marked another small milestone in using AI within the healthcare industry.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">While autonomous vehicles and humanoid robots are likely to be the largest applications of AI in the next five to ten years, health care is likely to be the most profound application: <a href="https://t.co/RorWkWFgSL">https://t.co/RorWkWFgSL</a>
&mdash; Cathie Wood (@CathieDWood) <a href="https://twitter.com/CathieDWood/status/1926337955272012273?ref_src=twsrc%5Etfw">May 24, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Before this, Wood made similar comments on the <a href="https://www.benzinga.com/government/regulations/25/05/45344120/cathie-wood-says-ai-innovation-in-healthcare-will-be-more-profound-than-autonomous-taxi-networks-humanoid-robots">use of AI for healthcare research</a>. According to ARK&#8217;s proprietary Multiomics Flywheel, "AI is powering a self-reinforcing loop that accelerates every aspect of multiomics—from generating biological data, to diagnosing diseases, to developing new drugs and cures."
Multiomics is a biological analysis approach that integrates data from multiple "omic" fields, like genomics, transcriptomics, proteomics, and metabolomics, to gain an understanding of biological systems.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">While autonomous taxi networks and humanoid robots are likely to be the largest <a href="https://twitter.com/hashtag/AI?src=hash&amp;ref_src=twsrc%5Etfw">#AI</a> applications during the next five and ten years, respectively, health care is likely to be the most profound. Thank you <a href="https://twitter.com/NMDespotARK?ref_src=twsrc%5Etfw">@NMDespotARK</a> for thought leadership in the multiomics space! <a href="https://t.co/C33JfypivU">https://t.co/C33JfypivU</a>
&mdash; Cathie Wood (@CathieDWood) <a href="https://twitter.com/CathieDWood/status/1921291392271167893?ref_src=twsrc%5Etfw">May 10, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/government/regulations/25/05/45344120/cathie-wood-says-ai-innovation-in-healthcare-will-be-more-profound-than-autonomous-taxi-networks-humanoid-robots">Cathie Wood Says AI Innovation In Healthcare Will Be More &#8216;Profound&#8217; Than Autonomous Taxi Networks, Humanoid Robots</a>
Why It Matters: Ark's multiomics analyst, Nemo M Despot, highlighted that companies like Twist Bioscience Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>), Tempus AI Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), 10X Genomics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXG#NASDAQ">TXG</a>), and Illumina Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) are developing increasingly powerful tools to sequence and analyze DNA faster and more cost-effectively.
Despot stated that AI-powered molecular diagnostics are changing how diseases are detected early and allowing for precise categorization of individual patient biological profiles.
"AI leverages data from multiomic tools and diagnostics to design more effective drugs, delivering results with higher success rates more quickly and less expensively," he said.
Price Action: The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, fell on Friday. The SPY was down 0.68% to $579.11, while the QQQ declined 0.93% to $509.24, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
On Monday, the futures of Dow Jones, S&amp;P 500, and Nasdaq 100 indices were trading higher.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45604427/donald-trumps-eu-tariff-extension-will-see-profit-booking-in-gold-this-is-the-beginning-of-a-currency-war-which-will-eventually-affect-gold">Donald Trump&#8217;s EU Tariff Delay Will See &#8216;Profit Booking In Gold:&#8217; &#8216;This Is The Beginning Of A Currency War, Which Will Eventually Affect Gold&#8230;&#8217; </a></li>
</ul>
Photo courtesy: ChrisStock82 / Shutterstock.com

Equities

Market Summary

Broad U.S. Equity ETFs

Futures

ETFs

TWST

Cathie Wood Reiterates 'Profound' AI Application In Healthcare As Researchers Discover 'Cancer Survival Outcomes' By Facial Photograph Analysis: Here Are The Stocks That Could Benefit

Analysts' ratings for Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) over the last quarter vary from bullish to bearish, as provided by 15 analysts.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">8</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $108.07, a high estimate of $185.00, and a low estimate of $77.00. A 18.66% drop is evident in the current average compared to the previous average price target of $132.87. 
<img src="https://www.benzinga.com/files/images/story/2025/1747746080_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A comprehensive examination of how financial experts perceive Illumina is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$105.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$185.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Tejas Savant</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$100.00</td>
<td>$136.00</td>
</tr>
<tr>
<td>Kyle Mikson</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$87.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Julia Qin</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$85.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Subbu Nambi</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$114.00</td>
<td>$122.00</td>
</tr>
<tr>
<td>Kyle Mikson</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$92.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$77.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Conor McNamara</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$112.00</td>
<td>$128.00</td>
</tr>
<tr>
<td>Patrick Donnelly</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$85.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Conor McNamara</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$128.00</td>
<td>$247.00</td>
</tr>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$156.00</td>
<td>$156.00</td>
</tr>
<tr>
<td>Kyle Mikson</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$115.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Catherine Ramsey</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$127.00</td>
</tr>
<tr>
<td>Patrick Donnelly</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$130.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Illumina. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Illumina compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Illumina's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Illumina's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ILMN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Illumina analyst ratings.</a>
<h2>Unveiling the Story Behind Illumina</h2>
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
<h3>Illumina's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3M period, Illumina faced challenges, resulting in a decline of approximately -3.25% in revenue growth as of 31 March, 2025. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Illumina's net margin excels beyond industry benchmarks, reaching 12.58%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Illumina's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 5.53% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Illumina's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.1%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a high debt-to-equity ratio of 1.1, Illumina faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 15 Analyst Ratings Have To Say About Illumina

Stephens &amp; Co. analyst Mason Carrico reiterates Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) with a Overweight and maintains $105 price target.

Reiteration

Stephens & Co. Reiterates Overweight on Illumina, Maintains $105 Price Target

Regeneron Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) announced Monday that it has secured the winning bid in the bankruptcy auction for key assets of 23andMe Holding Co. in a <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45489983/regeneron-enters-into-asset-purchase-agreement-to-acquire-23andme-for-256-million-plans-to-maintai" rel="noreferrer noopener">$256 million deal</a> to boost its genetics-based drug discovery efforts.
The acquisition includes 23andMe&#8217;s Personal Genome Service, Total Health, Research Services divisions, its Biobank, and associated infrastructure. Regeneron plans to keep consumer services running without disruption and expects the transaction to close in the third quarter of 2025.
Regeneron pledged to uphold 23andMe&#8217;s privacy policies to address concerns over data use and comply with all applicable regulations. A court-appointed Customer Privacy Ombudsman will review the intended data use and oversee privacy safeguards throughout the process.
Also Read: <a target="_blank" href="https://www.benzinga.com//node/44479516" rel="noreferrer noopener">23andMe&#8217;s Bankruptcy Sparks Privacy Concerns Over Genetic Database Of 15 Million Customers</a>
George D. Yancopoulos, Regeneron&#8217;s co-founder and chief scientific officer, emphasized the company&#8217;s long-term commitment to leveraging DNA in drug development.
He noted that Regeneron has already partnered globally to match de-identified genetic information from nearly three million participants with electronic health records, accelerating breakthroughs in treatments for cancer, infectious diseases, and immune disorders.
Aris Baras, head of the Regeneron Genetics Center, reaffirmed the company&#8217;s focus on ethical data use and scientific advancement. He said the acquisition supports Regeneron&#8217;s vision of utilizing large-scale genomic research to improve human health.
Following completion, 23andMe will become a wholly owned subsidiary of Regeneron. The transaction does not include the company&#8217;s Lemonaid Health division.
Regeneron held Cash and marketable securities of <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g45061738/regeneron-reports-first-quarter-2025-financial-and-operating-results" rel="noreferrer noopener">$17.625 billion</a> as of March 31, 2025.
Price Action: REGN shares traded lower by 0.66% to $590.40 at the last check Monday.
Photo by Michael Vi via Shutterstock

Biotech

IDNA

REGN

Genetic Data From 23andMe Ends Up With This Company In $256 Million Deal

<a href="https://www.benzinga.com/topic/carl-icahn">Carl Icahn is</a> making bold moves from the lab to the tarmac.
According to his latest <a href="http://edgar.secdatabase.com/619/153949725001390/filing-main.htm">13F filing</a> for the quarter ended March 31, the billionaire activist investor significantly boosted his holdings in Illumina Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) and JetBlue Airways Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBLU#NASDAQ">JBLU</a>) &#8211; a striking bet on both biotech and airlines.
Read Also: <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/04/44845918/carl-icahn-loads-up-cvr-energy-stock-drops-27-million-on-bullish-april-binge">Carl Icahn Loads Up CVR Energy Stock, Drops $27 Million On Bullish April Binge</a>
<h2 class="wp-block-heading">Three Of Icahn&#8217;s Top Holdings Are Healthcare Stocks</h2>
Icahn increased his stake in Illumina by 450%, adding 180,000 shares to bring his total holding to 220,000 shares. That holding now represents 0.25% of his $7 billion portfolio, up from just 0.07% previously. 
The genomics giant ranks 13th in Icahn's portfolio and was one of his top percentage gainers this quarter. The move signals renewed conviction in the embattled DNA sequencing company, which has been under pressure amid boardroom battles and regulatory scrutiny.
Icahn's top three healthcare holdings now include Bausch Health Companies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHC#NYSE">BHC</a>), Bausch + Lomb Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLCO#NYSE">BLCO</a>) and Illumina &#8211; a diverse mix that spans pharma, optics, and biotech.
But that wasn't the only high-flyer in Icahn's crosshairs.
<h2 class="wp-block-heading">JetBlue Boost &#8211; Turnaround Potential?</h2>
He nearly doubled down on JetBlue, boosting his stake by 89.66% with a purchase of nearly 15.9 million shares. 
Icahn now owns 33.6 million shares of the airline, worth over $162 million, making it the 7th largest position in his portfolio. That's up from 1.88% of the portfolio to 2.33%. Notably, Icahn first took a position in JetBlue in the first quarter of 2024, and the ramp-up suggests he sees serious turnaround potential.
While JetBlue and Illumina were among the top buys this quarter, Icahn trimmed exposure elsewhere, most notably Southwest Gas Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SWX#NYSE">SWX</a>), which saw a 1.96% drop in portfolio allocation.
With bets spanning DNA sequencing and discount air travel, Icahn&#8217;s latest moves show he's not afraid to invest where turbulence—literal or figurative—is part of the ride.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/asia/24/05/38878116/big-short-investor-michael-burry-bets-heavy-on-gold-renewable-energy-stocks-exits-amazon-alphabet">&#8216;Big Short&#8217; Investor Michael Burry Bets Heavy On Gold, Renewable Energy Stocks, Exits Amazon, Alphabet</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Hedge Funds

BLCO

JBLU

Icahn Ramps Up Bets On Genes And Jets: Illumina Stake Jumps 450%, JetBlue Holding Grow 90%

Illumina shares are trading higher after members of management disclosed stock purchases.

Piper Sandler analyst David Westenberg maintains Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) with a Overweight and lowers the price target from $190 to $185.

Piper Sandler Maintains Overweight on Illumina, Lowers Price Target to $185

Press Releases

Illumina To Webcast Upcoming Investor Conference

Illumina expands clinical oncology portfolio unlocking new standard of care and access to precision therapies

Illumina unveils PromoterAI, a groundbreaking algorithm to accelerate insights for rare disease diagnosis

lllumina releases 2024 Corporate Social Responsibility Report as it advances its vision to unlock the power of genomics

QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)

Infinity Bio Closes $8M Series A Financing Led by Illumina Ventures to Expand Leadership in Antibody Reactome Profiling

Standard BioTools Enters Next Phase of Transformation with Strategic Sale of SomaLogic to Illumina

Illumina to acquire SomaLogic, accelerating its proteomics business and advancing the company's multiomics strategy

"Mag 7 Undercard Movers: IBO, SNYR, CTOR, PNPN.V, LAB – Breakthroughs in Military Defense, Tech, Medical & Healthcare Fuel Market Buzz"

Management

iRhythm Technologies Announces Board Member Retirements and New Director Appointments

AIFF

ARAI

ATEC

CTOR

IRTC

NRXP

PNPNF

PRSO

SNYR

TSXV:PNPN

Agilent Technologies

AbCellera Biologics

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solutions

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Danaher

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

Illumina

Notizie

Ultime notizie per Illumina (NASDAQ:ILMN) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO